Founders published in Science, cover of Molecular Cell and trained at Nobel prize winning labs at MIT, UCSF & Harvard  

Founders have successful exits in the software industry having developed state of the art software

Access to global Thinkhat talent with multiple AI  products in the market.

Sequences provided in as little as 3 months from the initiation of contract

SQAAS (Sequence As A Service) offered as milestone driven contracts that Pay for Performance (P4P) only

Customized validation, Qualification Assay development for target sequences per client’s requirements.

Continuous learning based AI Engine “the Synapse” that refines sequence generation iteration over iteration

Leveraging the whole stack of central dogma with comprehensive omics including mass spec

Selective, highly efficient as well as immunogenic sequences provided.

Immunogenicity Forecasting: Advanced AI models forecast immunogenicity, minimizing the risk of adverse immune responses.

‍Target Cell Specificity: Deep learning algorithms predict how sequences will interact with specific cell types, ensuring targeted and effective treatments.

‍Drug Interaction Predictions: Our platform anticipates potential drug interactions, aiding in the design of safer and more effective therapies.